Newswise — Tumors that produce more stress granules are more likely to metastasize, according to a study published in The Journal of Cell Biology. The results suggest that drugs to inhibit the formation of these structures might rein in cancer metastasis.
When cells are under duress, they curtail almost all protein synthesis and stash their mRNAs in stress granules. These structures help healthy cells, but they also allow tumor cells to survive harsh conditions. A protein named YB-1, which is overexpressed in many types of tumors, accumulates in stress granules, but researchers don’t know how YB-1 affects these particles.
University of British Columbia scientist Poul Sorensen and his colleagues found that stressed-out cancer cells need YB-1 to assemble stress granules. Removing YB-1 decreased levels of one stress granule protein, G3BP1. The team discovered that YB-1 attaches to the mRNA encoding G3BP1 and stimulates the protein’s production.
To determine the effects of YB-1 in animals, the researchers implanted mice with cancer cells that either made or lacked the protein. A month later, cells in the control tumors carried more stress granules than did the tumor cells missing YB-1. Sorensen and colleagues then implanted mice with tumors that either produced or lacked G3BP1. The control tumors harbored more stress granules than did the G3BP1-deficient tumors, and only the control tumors metastasized.
Further research is needed to find out how the reduction in stress granules curbs metastatic spread, but the results suggest that inhibiting their formation might be a way to curb cancer metastasis.
Somasekharan, S.P., et al. 2015. J. Cell Biol. doi:10.1083/jcb.201411047
About The Journal of Cell Biology The Journal of Cell Biology (JCB) is published by The Rockefeller University Press. All editorial decisions on manuscripts submitted are made by active scientists in conjunction with our in-house scientific editors. JCB content is posted to PubMed Central, where it is available to the public for free six months after publication. Authors retain copyright of their published works, and third parties may reuse the content for non-commercial purposes under a creative commons license. For more information, please visit www.jcb.org.
Research reported in the press release was supported by the Terry Fox Research Institute, Prostate Cancer Canada-Movember Foundation, German Research Foundation , and British Columbia Cancer Foundation.